FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 240 filers reported holding FATE THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.68 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $415,647 | -83.4% | 41,194 | -63.1% | 0.25% | -82.7% |
| Q3 2022 | $2,500,000 | -15.1% | 111,545 | -6.1% | 1.43% | -19.6% |
| Q2 2022 | $2,943,000 | +17.4% | 118,778 | +83.7% | 1.78% | +11.5% |
| Q1 2022 | $2,507,000 | +85.7% | 64,665 | +180.2% | 1.59% | +48.3% |
| Q4 2021 | $1,350,000 | +32.9% | 23,081 | +34.7% | 1.08% | +60.0% |
| Q3 2021 | $1,016,000 | +5.2% | 17,134 | +54.0% | 0.67% | -1.9% |
| Q2 2021 | $966,000 | +75.0% | 11,128 | -19.4% | 0.68% | +70.4% |
| Q3 2020 | $552,000 | +29.0% | 13,807 | +10.8% | 0.40% | +13.6% |
| Q2 2020 | $428,000 | – | 12,463 | – | 0.35% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARCH Venture Management, LLC | 2,073,190 | $26,599,000 | 26.59% |
| Polaris Venture Management Co. V, L.L.C. | 1,823,186 | $23,391,000 | 24.97% |
| Casdin Capital, LLC | 2,550,000 | $32,717,000 | 5.60% |
| Redmile Group, LLC | 10,359,666 | $132,915,000 | 5.34% |
| Aquilo Capital Management, LLC | 697,096 | $8,944,000 | 4.33% |
| Eversept Partners, LP | 165,000 | $2,116,950 | 1.15% |
| Artal Group S.A. | 2,150,000 | $27,585,000 | 1.02% |
| AlpInvest Partners B.V. | 26,925 | $345,000 | 0.99% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 1,654,865 | $21,232,000 | 0.85% |
| Lisanti Capital Growth, LLC | 142,760 | $1,832,000 | 0.74% |